文献速递新发突发、热带与寄生虫病

减毒四价登革热疫苗诱导的型特异性与交叉反应性B细胞应答特征

Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
PubMed 文献 · J Infect Dis · 2021-01-01

该研究采用多色FluoroSpot法检测7只猕猴和15名TAK-003接种者(8名血清阴性、7名血清阳性)接种前后外周血单个核细胞中记忆B细胞应答。结果显示接种后所有个体均出现针对4种登革病毒血清型的型特异性和交叉反应性记忆B细胞,且型特异性比例更高并在接种后30至360天保持稳定。结论提示四价疫苗接种可诱导四价型特异性记忆B细胞,TAK-003四个组分均参与接种后登革病毒特异性记忆B细胞应答。

要点

  • TAK-003接种后诱导针对DENV1-4的型特异性和交叉反应性记忆B细胞。
  • 型特异性记忆B细胞比例高于交叉反应性,且接种后30至360天保持稳定。
  • 与自然感染不同,四价疫苗接种可诱导四价型特异性记忆B细胞应答。

核心结论

  • TAK-003四价疫苗接种诱导四价型特异性记忆B细胞,四个组分均参与接种后登革病毒特异性记忆B细胞应答。

研究设计与样本

  • 研究采用多色FluoroSpot法检测接种前后外周血单个核细胞中分泌登革病毒特异性抗体的记忆B细胞。
  • 样本包括7只猕猴和15名随机选取的TAK-003接种者(8名登革病毒血清阴性、7名血清阳性),来自新加坡II期临床试验DEN-205。

主要发现

  • 接种前仅血清阳性受种者在第0天检测到预先存在的登革病毒特异性记忆B细胞应答。
  • 接种后所有猕猴和临床试验参与者均出现针对全部4种登革病毒血清型的型特异性和交叉反应性记忆B细胞。
  • 型特异性记忆B细胞比例高于交叉反应性记忆B细胞,且在接种后第30天至第360天保持稳定。

临床怎么用

  • 四价登革热疫苗接种可诱导针对四个血清型的型特异性记忆B细胞,支持其四价组分均贡献于体液免疫应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dengue is caused by 4 antigenically distinct serotypes of dengue virus (DENV1-4). Takeda's live attenuated tetravalent dengue vaccine (TAK-003) candidate is composed of an attenuated DENV2 and chimeric viruses containing prM/E of DENV1, 3 and 4 on the DENV2 backbone. The multicolor FluoroSpot (MCF) assay enables quantitation of serotype-specific and cross-reactive individual memory B cells (MBCs) secreting DENV-specific antibodies in a polyclonal mixture. METHODS: Using the MCF assay, we determined the type-specific and cross-reactive MBC response in peripheral blood mononuclear cells collected pre- and postvaccination from 7 macaques and 15 randomly selected individuals who received TAK-003 (8 DENV seronegative and 7 DENV seropositive) in a phase 2 clinical trial in Singapore (DEN-205 study). RESULTS: Preexisting DENV-specific MBC responses were detected only in seropositive vaccine recipients at day 0. Following vaccination, both type-specific and cross-reactive MBCs to all 4 DENV serotypes were observed in all macaques and clinical trial participants. The proportion of type-specific MBCs was higher than cross-reactive MBCs and remained stable between day 30 and 360 post vaccination. CONCLUSIONS: These results demonstrate that, unlike primary or secondary natural DENV infection, tetravalent vaccination elicits tetravalent type-specific MBCs, and thus all 4 components of TAK-003 contribute to the DENV-specific MBC response following vaccination. CLINICAL TRIALS REGISTRATION: NCT02425098.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Michlmayr D, Andrade P, Nascimento EJM, et al. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. J Infect Dis. 2021. PMID: 32572472. doi:10.1093/infdis/jiaa346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。